

08-01-02

GP1647

#5  
8/23/02

**PATENT**

**THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**RIDET ET AL.**

Examiner: **UNASSIGNED**

Art Unit: **UNASSIGNED**

Application No.: **09/868,026**

Filed: **JANUARY 11, 2002**

**RECEIVED**

AUG 06 2002

Title: **HUMAN ADULT ASTROCYTES, THEIR  
PREPARATION AND USES THEREOF**

TECH CENTER 1600/2900

**CERTIFICATE OF MAILING UNDER 37 CFR 1.10**

I hereby certify that this correspondence is being deposited with the United States Postal Service via EXPRESS MAIL with EXPRESS MAIL Label No. EL886503724US in an envelope addressed to the COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 on August 1, 2002.

William C. Coppola, Reg. No. 41,686  
(Name of Registered Representative)

(Signature and Date)

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in § 1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in § 1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits,

whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

(b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under § 1.113 or a notice of allowance under § 1.311, whichever occurs first.


(1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;

(2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; or

(3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in § 1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Enclosed is a completed form 1449 along with copies of all references cited in the form.

Respectfully submitted,



William C. Coppola, Reg. No. 41,686

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-4854  
Telefax (908) 231-2626

Aventis Docket No. A3400 US PCT